Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report issued on Thursday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright decreased their price objective on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th.

Minerva Neurosciences Stock Down 2.7 %

NASDAQ NERV opened at $2.51 on Thursday. The company has a market cap of $17.55 million, a PE ratio of -0.56 and a beta of 0.14. Minerva Neurosciences has a 52 week low of $2.26 and a 52 week high of $13.49. The firm’s 50-day simple moving average is $2.70 and its two-hundred day simple moving average is $2.80.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.12). As a group, equities research analysts anticipate that Minerva Neurosciences will post -2.26 EPS for the current year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.